The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Prevention (CSAP), is accepting applications for fiscal year (FY) 2011 Strategic Prevention Framework State Prevention Enhancement grants (Short Title: SPE grants). These awards are designed to strengthen and extend SAMHSA's national implementation of the Strategic Prevention Framework (SPF), so as to bring the SPF to scale and support communities of high need nationwide (see Part I, Section 2.2 for more details). The SPF process is an integral part of SAMHSA's mission to reduce the impact of substance abuse and mental illness on America's communities. (�Communities,� in the broadest sense, should include community coalitions, which play a vital role in creating successful State and Tribal prevention systems.) With a broad, national scope, the SPE Program is designed to support States, Territories and Tribes (hereinafter referred to as States and Tribes) in enhancing their infrastructures to reduce the impact of substance abuse. Through stronger, more strategically aligned substance abuse infrastructures, SPE States and Tribes will be better positioned to apply the SPF process to implement data-driven, evidence-based prevention programs, policies and practices in their communities. These 1-year SPE cooperative agreements are intended to support States, Territories and Tribal entities in strengthening and enhancing their current prevention infrastructure to support more strategic, comprehensive systems of community-oriented care. SPE funding will foster more responsive, interactive State and Tribal systems that can better address and adjust to the complexities of evolving health care initiatives and their fiscal implications for communities of high need. The SPE Program calls upon Single State Agency Directors and Tribal Leaders to capitalize on their State or Tribe's ability to implement the SPF process, to assess the current state of their prevention infrastructure, identify gaps and develop a long-term, data-driven strategic plan to restructure, enhance and further strengthen their State and Tribal system to better meet the emerging needs of populations throughout their communities. It provides the foundation for assuring that behavioral health plays an essential role in responding to the Nation's rapidly evolving health care delivery system. It is rooted in the belief that SAMHSA's State and Tribal grantees have a pivotal, strategic role to play at this time in helping to shape the direction and implementation of their State-wide systems in support of SAMHSA's overall prevention mission. Key SPE grant requirements include the development and submission to SAMHSA/CSAP of two State/Tribal plans: 1) a Capacity Building/Infrastructure Enhancement Plan at the end of the 3rd month of the grant and 2) a comprehensive, 5-year Strategic Prevention Plan at the end of the 11th month of the grant. The Strategic Prevention Plan must provide a description of progress and accomplishments made to date, outline the work that remains to be done, and provide an action plan for the future, with action steps, estimated timelines, available resources and responsible parties. SPE grants are authorized under Section 516 of the Public Health Service Act, as amended. This announcement addresses Substance Abuse Topic Area HP 2020-SA. This RFA addresses SAMHSA's Strategic Initiative #1: Prevention of Substance Abuse and Mental Illness. SAMHSA strongly encourages all grantees to provide a smoke-free workplace and to promote abstinence from all tobacco products (except in regard to accepted Tribal traditions and practices.) Addressing SAMHSA's Goals for Prevention Grantees must ensure that their SPE projects address and are closely aligned with the four goals listed in SAMHSA Initiative #1: Prevention of Substance Abuse and Mental Illness; and with two other SPE-specific goals (i.e., workforce development and policy development) as listed below. Additionally, grantees must ensure that all components of their Capacity Building/Infrastructure Enhancement Plan and their 5-year, comprehensive Strategic Plan align closely with these goals. (In the sections below, we provide detailed discussion about these two important plans and other SPE requirements.) SAMHSA Initiative #1 Goals Goal 1.1: With primary prevention as the focus, build emotional health, prevent or delay onset of, and mitigate symptoms and complications from substance abuse and mental illness. Goal 1.2: Prevent or reduce consequences of underage drinking and adult problem drinking. Goal 1.3: Prevent suicides and attempted suicides among populations at high risk, especially military families, LGBTQ youth, or American Indians and Alaska Natives. Goal 1.4: Reduce prescription drug misuse and abuse. Additional SPE-specific Goals Enhance State/Tribal workforce development (e.g., training, support for licensure, credentialing, or accreditation). Enhance State/Tribal Policy development to support needed service system improvements (e.g., rate-setting activities, establishment of standards of care, development/revision of credentialing, licensure, or accreditation requirements). Funding Opportunity Number: SP-11-004. Assistance Listing: 93.243. Funding Instrument: G. Category: HL. Award Amount: Up to $600K per award.

This FOA issued by the National Eye Institute (NEI), National Institutes of Health (NIH), encourages applications from institutions/organizations that propose to conduct secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects, wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support but such data are of the highest programmatic interest. The R21 may be used to develop new statistical methodologies or to test hypotheses using existing data, but this FOA may not be used to support the collection of new data. Funding Opportunity Number: PAR-13-035. Assistance Listing: 93.867. Funding Instrument: G. Category: HL. Award Amount: Up to $200K per award.

This Funding Opportunity Announcement (FOA) will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based, exploratory projects may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational levels. Funding Opportunity Number: RFA-DA-23-015. Assistance Listing: 93.279. Funding Instrument: G. Category: ED,HL. Award Amount: Up to $350K per award.

The purpose of this FOA is to support a collection of research networks that promote multidisciplinary mechanistic studies of music-based interventions (MBIs) for pain or Alzheimers disease and Alzheimers disease related dementias (AD/ADRD). These networks are expected to develop compelling research frameworks that will guide future clinical research on MBIs in these health conditions effectively, adopt consistent terminology and taxonomy, support interdisciplinary collaborations, initiate pilot projects testing novel mechanistic hypotheses, and identify strong mechanistic measures, outcomes, biomarkers, as well as relevant novel technologies and methodologies. To accomplish these objectives, applicants can propose activities such as meetings, workshops, conferences, research collaborations, exchange of ideas through visiting scientist arrangements and training opportunities. The research networks would also provide opportunities for development of pilot projects addressing research gaps identified through network meetings and collaborative discussions, providing the necessary preliminary data needed for music and health investigators to compete for more substantial NIH grants. In addition, the networks should also engage in dissemination activities that promote and sustain their scientific impact through publications of research frameworks, common terminologies, reviews, and best practices as well as other outreach and communication strategies. Funding Opportunity Number: RFA-AT-23-006. Assistance Listing: 93.213,93.866. Funding Instrument: CA. Category: HL. Award Amount: Up to $300K per award.

Through this Funding Opportunity Announcement (FOA), NCI, NIDA, and NCCIH invite Cooperative Agreement (U01) applications that propose prospective research studies to assess the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment. NCI, NIDA, and NCCIH are seeking well-designed prospective cohort studies of cancer patients with solid or hematologic tumors currently receiving treatment. Studies are expected to compare cancer patients who use cannabis/cannabinoids with cancer patients that do not use cannabis and/or cannabinoids. Research studies including diverse populations by age, sex, race/ethnicity, tumor types, and/or geography and propose population-based recruitment strategies using cancer registries are strongly encouraged. This FOA is published in parallel with RFA-CA-22-053 "Coordinating Center for Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed). New prospective studies and the coordinating center funded under these FOAs will work together with NIH program staff. Funding Opportunity Number: RFA-CA-22-052. Assistance Listing: 93.213,93.279,93.393. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $500K per award.

The purpose of this FOA is to support basic research on signaling pathways and mechanisms including HIV-host protein interactions and post-translational modifications by which addictive drugs and HIV infection converge to induce changes in brain function and cause neuropathological alterations and neurocognitive dysfunctions. This FOA also aims to promote discovery and development of novel chemical and biological approaches for prevention or mitigation of CNS complications associated with HIV infection and substance use disorders. Funding Opportunity Number: RFA-DA-24-014. Assistance Listing: 93.279. Funding Instrument: G. Category: ED,HL. Award Amount: Up to $275K per award.

The purpose of this initiative is to advance hematopoietic cell transplantation (HCT) for all patients, but particularly for patients with rare and difficult to treat non-malignant blood diseases and hematological malignancies. This will be accomplished by supporting a clinical trials network to evaluate novel cell therapy (CT) and HCT approaches. A Data Coordinating Center (DCC) and core clinical sites will be supported by funds requested as part of this initiative, as well as a limited number of trials. Additional studies and trials will be funded through collaborations with R01-funded grantees, industry, and foundations. Multiple factors extend the duration of most HCT and CT trials beyond 5 years, including rare patient populations (and hence accrual periods of up to 5 years), complex cell manufacturing processes, and composite endpoints such as disease-free survival and chronic graft versus-host disease free survival that occur 2 or more years post-transplant. A seven year program to support these activities is needed. Funding Opportunity Number: RFA-HL-24-010. Assistance Listing: 93.395,93.839. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.

The purpose of this RFA is to stimulate research on the development and evaluation of tobacco cessation interventions for adolescents, with an emphasis on ages 14-20. We have chosen to focus on this developmental period because it represents the area of greatest need with respect to the existing evidence on use patterns and treatment gaps. It also targets the developmental risk period for which we will see the maximum benefit from early intervention. Funding Opportunity Number: RFA-CA-22-042. Assistance Listing: 93.279,93.393. Funding Instrument: G. Category: ED,HL. Award Amount: Up to $450K per award.

The intersection of criminal-legal and community-based health systems is a critical target for addressing the overdose crisis. To support research on effective interventions and implementation strategies, the National Institute on Drug Abuse intends to continue the Justice Community Overdose Innovation Network (JCOIN) Phase II. The purpose of the network is to bring together a national consortium of investigators and practitioner partners to conduct an array of research and capacity building activities to address the overdose epidemic among individuals involved in the criminal-legal system. The structure of the network shall consist of three highly integrated components - (1) Research Hubs; (2) a single, central Coordination and Translation Center; and (3) a single, central Methodology and Advanced Analytics Resource Center. This NOFO solicits applications for a Coordination and Translation Center. This NOFO runs in parallel with a companion NOFO for the Methodology and Advanced Analytics Resource Center (NOT-DA-24-068); a NOFO for Research Hubs is anticipated at a future date (NOT-DA-25-025). Funding Opportunity Number: RFA-DA-24-069. Assistance Listing: 93.279,93.865. Funding Instrument: CA. Category: ED,HL,ISS.

This Notice of Funding Opportunity (NOFO) invites applications to continue critical ongoing network and infrastructure support for advancing development in a specific high-priority area of behavioral and social research on Alzheimers disease (AD) and AD-related dementias (ADRD): The Harmonized Cognitive Assessment Protocol (HCAP) International AD/ADRD Research Network. Network/infrastructure-building activities include but are not limited to meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots to test or tailor measures in new populations or contexts; development of guidance on selected topics such as biomarkers, diagnosis and classification of dementia, protocol development, fieldwork challenges, statistical harmonization, and analytic methods; educational activities such as intensive summer institutes, series of workshops and related network activities, or advanced seminars on methodology; dissemination and outreach activities; and coordinate activities with other related networks on AD/ADRD. Funding Opportunity Number: RFA-AG-24-035. Assistance Listing: 93.866. Funding Instrument: CA. Category: HL. Award Amount: Up to $385K per award.

As part of the NIH's Helping to End Addiction Long-term (HEAL) Initiative, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and participating NIH Institutes and Centers invite applications to this U01 Cooperative Agreement funding opportunity to support innovative, multi-site, large-scale investigator-initiated clinical trials to advance the understanding, assessment, measurement, treatment, and prevention of acute pain in infants, children, and adolescents, including those with disabilities and/or experiencing health disparities. Clinical trials testing behavioral interventions to manage pain as the primary outcome(s) will not be considered as high priority projects. This Notice of Funding Opportunity (NOFO) runs in parallel with a companion NOFO (RFA-HD-24-012) that invites applications for a single HEAL KIDS Pain Resource and Data Center (RDC) to provide the following: leadership in data management, data curation, data harmonization, and the development of data standards; administrative and logistical support including oversight of NIH HEAL-related requirements; and coordination of shared research-related resources for all of the HEAL KIDS Pain research activities. Funding Opportunity Number: RFA-HD-24-011. Assistance Listing: 93.121,93.213,93.233,93.361,93.395,93.396,93.399,93.837,93.838,93.839,93.840,93.846,93.847,93.853,93.865,93.866. Funding Instrument: CA. Category: ED,FN,HL,ISS.

Reissue of RFA-NS-19-011: The purpose of the NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students who are from backgrounds that are nationally underrepresented in neuroscience research. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers. Funding Opportunity Number: RFA-NS-21-012. Assistance Listing: 93.113,93.121,93.213,93.242,93.273,93.279,93.286,93.853,93.865,93.866,93.867. Funding Instrument: G. Category: ED,ENV,HL,ISS.

This 5-year project’s purpose is to continue collaboration with counterparts in China to reduce the threat of infectious disease transmission, in China, the U.S. and the world. This collaboration contributes to enhancing the technical collaboration, scientific exchange, and effective communication to promote health through trusted and robust partnerships between U.S. CDC and counterparts in China. The program has three broad goals: 1) strengthen public health systems and workforce capacity, 2) decrease the burden of TB, and 3) reduce influenza morbidity and mortality and enhance preparedness for pandemic threats. Activities may include joint investigations and monitoring of disease outbreaks, piloting innovative public health interventions, translating programmatic success to practice and policy, working in third countries to jointly respond to a public health emergency, and promoting rapid and transparent dissemination of public health data. This collaboration strives to leverage the expertise in China to share knowledge and evidence-based science for a bi-lateral exchange that mutually benefits the U.S. and China. By identifying governmental, non-governmental, multilateral, and private sector organizations in China, the partnership builds sustainable expertise and capacity in global health security and public health systems. Depending on funding availability and priorities, the specific infectious disease entities to be addressed can change over the period of performance. Funding Opportunity Number: CDC-RFA-JG-24-0131. Assistance Listing: 93.318. Funding Instrument: CA. Category: HL. Award Amount: $5M total program funding.

This Notice of Funding Opportunity (NOFO) invites grant applications from institutions/organizations that propose to build a Medical Rehabilitation Research Center. The centers will have a specific rehabilitation research theme and be comprised of a research project supported by 3 cores. The 3 cores will have functions within the center as well as functions nationwide. Together, the cores will support: administrative functions (including an optional pilot program), resource sharing, and community engagement and outreach. The Medical Rehabilitation Research Centers will contribute tomedical rehabilitation research infrastructure by developing and disseminating techniques, data, theories, research programs, and expertise with the goal of enhancing the capability of medical rehabilitation investigators to understand mechanisms of functional recovery, develop therapeutic strategies, identify clinical care gaps, and improve the lives of people with disabilities. Applications must include a plan for inclusion of People with Lived Experience (as a required other attachment) that is relevant to the research theme of the center and increases the potential impact of the center. Funding Opportunity Number: RFA-HD-25-001. Assistance Listing: 93.173,93.213,93.279,93.286,93.865. Funding Instrument: G. Category: ED,HL,ISS.

(Reissue of RFA-NS-16-021, PAR-18-413, RFA-NS-19-039) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or cerebellum. Though most commonly extending out from the periventricular surfaces, it may also occur in subcortical white matter. Diffuse white matter disease is typically detected in clinical settings as hyperintensity on magnetic resonance imaging (MRI) or signal loss on computed tomography x-ray (CT) scan; diffuse white matter disease can be detected histologically as well, for example in human pathology and in studies using animal models. Despite the prevalence and potential significance of white matter disease for cerebrovascular disease etiology and cognitive outcomes, much remains to be learned about the cellular and molecular causes, regional vulnerability, and progression over time. The physiological consequences of diffuse white matter disease on local axon and neural circuit function are almost completely unknown. The purpose of this FOA is to address some of the many gaps in knowledge of the biologic mechanisms of the commonly occurring, cerebrovascular disease and age-related diffuse white matter disease at the molecular, cellular, tissue and brain circuit level. The ultimate goal of this fundamental research is to inform future efforts to reduce the burden of illness due to age-related vascular contributions to cognitive impairment and dementia. Funding Opportunity Number: PAR-24-196. Assistance Listing: 93.853,93.866. Funding Instrument: G. Category: HL. Award Amount: Up to $500K per award.

The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the establishment ofeffective and reliable biomarkers of Alzheimers disease (AD) and AD-related dementias (ADRD) for usein therapy/medical product discovery and development, clinical trials and/or clinical practice. Specifically, this NOFO willsupport analytical and/or clinical validationof a biomarker, composite biomarker or biomarker signature, withrigor comparable with the expectations described in the Food and Drug Administration (FDA)Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways. Funding Opportunity Number: PAR-23-258. Assistance Listing: 93.866. Funding Instrument: CA. Category: HL.

This notice of funding opportunity (NOFO) invites applications from eligible organizations to establish the New Approach Methodologies (NAMs) Data Hub and Coordinating Center (NDHCC) for the NIH Common Fund Complement Animal Research In Experimentation (Complement-ARIE) program. The goal of Complement-ARIE is to implement better models for understanding human health and disease outcomes across a broad array of populations that complement traditional models and make biomedical research more efficient and effective. The award made through this announcement will support Complement-ARIE by providing a centralized data hub, building a searchable repository for various NAMs data types, establishing standards for data reporting and model credibility, developing and implementing an Integrated Testing Strategies (ITS), developing strategies for interoperability, sustainability data reuse, and developing tools for data analytics, dissemination, and sharing. The awardee will also serve as the coordinating center for the overall Complement-ARIE program. Funding Opportunity Number: RFA-RM-24-013. Assistance Listing: 93.310. Funding Instrument: CA. Category: HL.

Pre-exposure prophylaxis, also known as PrEP, is a safe, highly effective medication for preventing transmission of HIV from sex or injection drug use. Despite PrEPs high efficacy and its availability for over a decade, the awareness, uptake, and adherence of PrEP, especially among people who use substances remain suboptimal. The goal of this concept is to support research to examine and address systemic and structural factors that impede or facilitate the PrEP awareness, uptake, and adherence, among people who use substances. Projects will develop, implement, and evaluate effective strategies that meet the needs of people who use substances to improve the PrEP care continuum. Funding Opportunity Number: RFA-DA-26-003. Assistance Listing: 93.279,93.307,93.310,93.313. Funding Instrument: G. Category: ED,HL. Award Amount: Up to $500K per award.

The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (R00) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. This NOFO offers the opportunity for current RFA-HL-20-001 or RFA-HL-20-002 K99 awardees to apply for the independent phase (R00) of the program. In the R00 phase, successful blood science physician scientist scholars will receive up to three years of funding to continue their research activity with support from this FOA, which will require updated research plans and a limited competition review. Funding Opportunity Number: RFA-HL-26-001. Assistance Listing: 93.838. Funding Instrument: G. Category: HL. Award Amount: Up to $250K per award.

Drinking Water State Revolving Fund (DWSRF) is a financial assistance program from NYS EFC and NYS Department of Health providing low-interest loans and grants to upgrade drinking water infrastructure in New York State. Eligible borrowers include community water systems and nonprofit non-community water systems. Projects must be listed on the Department of Health's Intended Use Plan (IUP) before applying. The program prioritizes projects addressing public health risks, aging infrastructure, and emerging contaminant compliance, with enhanced funding available through the Infrastructure Investment and Jobs Act.

NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.

BrightFocus Foundation Alzheimer's Disease Research Grants is a grant from BrightFocus Foundation that funds pioneering biomedical research aimed at understanding, preventing, and treating Alzheimer's disease. The program supports both U.S. domestic and international researchers conducting early-stage and translational research across the stages of discovery. Priority areas include molecular mechanisms of disease, novel therapeutic targets, and clinical interventions. Eligible applicants include scientists and institutions worldwide. Awards support multi-year research projects, with funding levels and deadlines announced annually via a Request for Proposals.

Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by NSF CISE. Supports the development of transformative high-risk, high-reward advances in computer and information science, engineering, mathematics, statistics, behavioral and/or cognitive research to address pressing questions in the biomedical and public health communities.

NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required) is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Supports clinical trials that prospectively assign human participants to conditions to assess biomedical or behavioral outcomes, focusing on fundamental aspects of phenomena without specific application towards processes or products in mind.

Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.

The Biomedical Catalyst – Industry-led R&D (Small Projects) is a grant from Innovate UK (part of UKRI) that funds the development of innovative solutions to health and healthcare challenges. The programme supports small-scale industry-led R&D projects and is open to both single applicants and collaborative teams. Eligible applicants are UK-registered micro, small, and medium-sized enterprises (SMEs). A total of up to £25 million is available across the competition, with applications closing on 10 December 2025. To lead or work alone on a project, organisations must hold UK SME status and register through the Innovation Funding Service.

Developing Agency, Identity and Belonging in Young People is sponsored by The Colorado Health Foundation. Provides support for programs that offer safe, welcoming spaces for youth (BIPOC, LGBTQIA2S+, etc.) to develop relationships, community connection, and resilience outside of school or home. Geographic focus: Colorado Focus areas: Thriving Young People, Health Equity, Social-Emotional Development

The purpose of this notice of funding opportunity (NOFO) is to support the investigation of HIV-1 Envelope (Env) cell surface expression, the structural mechanism of biologic-mediated cell killing, and the development of novel approaches to enhance the recognition and elimination of Env-expressing, HIV-1 infected cells. These studies are expected to inform the development of immunotherapies and targeted vaccines for HIV-1 prevention and cure. Funding Opportunity Number: PAR-25-300. Assistance Listing: 93.855. Funding Instrument: G. Category: HL.

Connected Healthy Lives Grant Cycle is a grant from the Humana Foundation that funds organizations advancing health equity through innovative programs addressing the social determinants of health. The Humana Foundation directs its grantmaking around four core commitment areas, with a Health Equity Innovation Fund supporting bold, transformative approaches. Grants range from $50,000 to $2,500,000, with single-year and multi-year proposals accepted. Applicants must establish an organizational profile and complete an eligibility check through the Humana Foundation's SmartSimple grant management portal before submitting a proposal.

The Bicycle Helmet Initiative is a grant from the North Carolina Department of Transportation that funds organizations distributing free bicycle helmets to promote cyclist safety across the state. The program provides 25 to 100 helmets per recipient, valued at approximately $500 to $2,000. Eligible applicants include North Carolina government entities, nonprofits, schools, churches, and public health agencies committed to bicycle safety education and outreach. The most recent application deadline was February 20, 2026. This initiative supports the state's broader Safe Routes to School and pedestrian and bicycle safety goals by ensuring cost is not a barrier to helmet access for North Carolina communities.